KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
2011
|
| Online-Zugang: | Volltext Volltext |
| Beschreibung: | Aus: Oncology ; 81. 2011 |
| Beschreibung: | 1 Online-Ressource |
Internformat
MARC
| LEADER | 00000nmm a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV040774693 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 130225s2011 |||| o||u| ||||||eng d | ||
| 024 | 7 | |a urn:nbn:de:bvb:29-opus-42936 |2 urn | |
| 035 | |a (OCoLC)828812266 | ||
| 035 | |a (DE-599)BVBBV040774693 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 | ||
| 245 | 1 | 0 | |a KRAS mutation in metastatic pancreatic ductal adenocarcinoma |b results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy |c F. Kullmann ... |
| 264 | 1 | |c 2011 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Aus: Oncology ; 81. 2011 | ||
| 700 | 1 | |a Kullmann, F. |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u https://open.fau.de/handle/openfau/3037 |x Verlag |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:bvb:29-opus-42936 |x Resolving-System |z kostenfrei |3 Volltext |
| 912 | |a ebook | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-025753033 | ||
Datensatz im Suchindex
| _version_ | 1804150105551405056 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV040774693 |
| collection | ebook |
| ctrlnum | (OCoLC)828812266 (DE-599)BVBBV040774693 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01111nmm a2200301 c 4500</leader><controlfield tag="001">BV040774693</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">130225s2011 |||| o||u| ||||||eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">urn:nbn:de:bvb:29-opus-42936</subfield><subfield code="2">urn</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)828812266</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV040774693</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">KRAS mutation in metastatic pancreatic ductal adenocarcinoma</subfield><subfield code="b">results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy</subfield><subfield code="c">F. Kullmann ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Aus: Oncology ; 81. 2011</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kullmann, F.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://open.fau.de/handle/openfau/3037</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:29-opus-42936</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025753033</subfield></datafield></record></collection> |
| id | DE-604.BV040774693 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T00:33:38Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025753033 |
| oclc_num | 828812266 |
| open_access_boolean | 1 |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | 1 Online-Ressource |
| psigel | ebook |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| record_format | marc |
| spelling | KRAS mutation in metastatic pancreatic ductal adenocarcinoma results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy F. Kullmann ... 2011 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Aus: Oncology ; 81. 2011 Kullmann, F. Sonstige oth https://open.fau.de/handle/openfau/3037 Verlag kostenfrei Volltext https://nbn-resolving.org/urn:nbn:de:bvb:29-opus-42936 Resolving-System kostenfrei Volltext |
| spellingShingle | KRAS mutation in metastatic pancreatic ductal adenocarcinoma results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy |
| title | KRAS mutation in metastatic pancreatic ductal adenocarcinoma results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy |
| title_auth | KRAS mutation in metastatic pancreatic ductal adenocarcinoma results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy |
| title_exact_search | KRAS mutation in metastatic pancreatic ductal adenocarcinoma results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy |
| title_full | KRAS mutation in metastatic pancreatic ductal adenocarcinoma results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy F. Kullmann ... |
| title_fullStr | KRAS mutation in metastatic pancreatic ductal adenocarcinoma results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy F. Kullmann ... |
| title_full_unstemmed | KRAS mutation in metastatic pancreatic ductal adenocarcinoma results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy F. Kullmann ... |
| title_short | KRAS mutation in metastatic pancreatic ductal adenocarcinoma |
| title_sort | kras mutation in metastatic pancreatic ductal adenocarcinoma results of a multicenter phase ii study evaluating efficacy of cetuximab plus gemcitabine oxaliplatin gemoxcet in first line therapy |
| title_sub | results of a multicenter phase II study evaluating efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy |
| url | https://open.fau.de/handle/openfau/3037 https://nbn-resolving.org/urn:nbn:de:bvb:29-opus-42936 |
| work_keys_str_mv | AT kullmannf krasmutationinmetastaticpancreaticductaladenocarcinomaresultsofamulticenterphaseiistudyevaluatingefficacyofcetuximabplusgemcitabineoxaliplatingemoxcetinfirstlinetherapy |